BCN-CP01

N/A

Report date: 2025/04/25 11:15:56

Base Information

Drug NameBCN-CP01

Drug Alias NameBCN-CP01BCN CP01BCN-CP-01GLPG5201GLPG-5201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellPoint BV

China Registration ClassN/A

Develop Information

Active CompaniesCellPoint BV

Inactive CompaniesN/A

Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A